Section Arrow
INSM.NASDAQ
- Insmed Incorporated
Quotes are at least 15-min delayed:2025/09/04 04:00 EDT
Pre Market
Last
 --
-- (--)
Bid
128.47
Ask
147
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 143.5
-1.8 (-1.24%)
Day High 
146.8399 
Prev. Close
145.3 
1-M High
146.52 
Volume 
2.50M 
Bid
128.47
Ask
147
Day Low
142.36 
Open
145 
1-M Low
106.54 
Market Cap 
30.71B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 133.25 
20-SMA 125.74 
50-SMA 111.66 
52-W High 146.8399 
52-W Low 60.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.67/-2.83
Enterprise Value
31.85B
Balance Sheet
Book Value Per Share
5.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
11.70M
Operating Revenue Per Share
1.33
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
Pre Market -- -- --
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
Pre Market 0.0572 +0.0046 +8.75%
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
Pre Market 0.3497 -0.0202 -5.46%
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
Pre Market 2.45 -0.07 -2.78%
STTKShattuck Labs1.28+0.27+26.73%-- 
Pre Market 1.25 -0.03 -2.34%
Quotes are at least 15-min delayed:2025/09/04 04:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.